20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
07:00 , Sep 29, 2014 |  BC Week In Review  |  Company News

Silarus Therapeutics Inc., Thyritope Biosciences Inc., GlaxoSmithKline hematology, endocrine/metabolic, autoimmune news

Avalon Ventures and GlaxoSmithKline launched Silarus and Thyritope. Each company may receive up to $10 million in series A financing, comprising $3 million in equity investment from Avalon and up to $7 million in R&D...
07:00 , Sep 29, 2014 |  BioCentury  |  Finance

Avalon-GSK bet on familiarity, speed

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Avalon Ventures' double launch of iron play Silarus Therapeutics Inc. and autoimmune company Thyritope Biosciences Inc. shows one more element the pharma likes about the partnership's 2013 deal to fund...
03:09 , Sep 23, 2014 |  BC Extra  |  Company News

Avalon, GSK launch two newcos

Avalon Ventures and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) launched Silarus Therapeutics Inc. (San Diego, Calif.) and Thyritope Biosciences Inc. (San Diego, Calif.). Each may receive up to $10 million in series A financing, comprising $3 million...
07:00 , Jul 17, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Hematology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Thalassemia Family with sequence similarity 132 b (FAM132b; erythroferrone; myonectin) Mouse studies suggest erythroferrone antagonists could...